Major Boost for Innovative Drugs: China Medicine Registration System Officially Launched in Beijing

On December 2, 2025, the launch ceremony for China’s Drug Price Registration System, co-hosted by the National Healthcare Security Administration and the Beijing Municipal People’s Government, was grandly held at the New Dynamics Fintech Center in Xicheng District, Beijing. The establishment of this authoritative information platform, led at the national level, marks a milestone step forward in improving China’s drug price formation mechanism, supporting the high-quality development of the pharmaceutical industry, and deeply integrating into the global pharmaceutical market.

Across major global pharmaceutical markets, establishing transparent and authoritative mechanisms for drug price information disclosure and protection is an internationally accepted norm for balancing innovation incentives, market access, and payment sustainability. The establishment of China’s Drug Price Registration System is not an isolated initiative, but a strategic move that demonstrates a deep understanding of and proactive integration into global industry rules. International practice shows that mature pharmaceutical markets generally employ diversified and open price management systems to balance local accessibility with global competitiveness. On one hand, they protect the value of innovative drugs through price confidentiality and zone-based pricing. “Price protection for innovative drugs” ensures that R&D investments receive corresponding returns across different global markets.

On the other hand, major economies are striving to build official price disclosure and transparency systems to enhance market efficiency and credibility. In the past, international drug transactions and pricing references largely relied on data from commercial research firms. Today, drawing on established international practices, China has officially launched the China Drug Price Registration System, filling the gap in a national-level official platform for price information.

China Drug Price Registration System, aligned with international practices. Independently operated from provincial procurement platforms, it was jointly launched by the National Healthcare Security Administration and the Beijing Municipal Government, with its authority and credibility benchmarked against international government-level platforms. Pioneeringly integrating “voluntary registration” with “confidentiality services,” the system provides a globally trusted “price identity card” for Chinese innovative drugs going global, while removing institutional barriers for multinational pharmaceutical companies to introduce their innovative products into China at appropriate prices without concern. By leveraging high-quality services to reduce information asymmetry in the global market, it lays a solid foundation of national credit for building a scientific and diversified drug pricing system.

According to the head of the Pricing and Procurement Department of the National Healthcare Security Administration, in the first three quarters of 2025, Chinese pharmaceutical companies completed more than 103 overseas licensing transactions, with the total transaction value exceeding $92 billion. This trend has increasingly highlighted the reference value of China’s end-market prices for the global development of innovative drugs.

The core challenge for Chinese innovative drugs in “going global” lies in breaking free from the constraints of a single pricing system and achieving international pricing that aligns with their clinical value. In the past, it was difficult for companies to gain the trust of international payers without providing official price documentation when expanding overseas. An overly uniform pricing system has severely hindered the realization of the value of Chinese innovative drugs.

In July 2025, the release of “Several Measures to Support the High-Quality Development of Innovative Drugs” charted a clear roadmap for resolving this challenge, explicitly proposing support for the establishment of a diversified pricing system. The China Drug Price Registration System serves as the critical infrastructure that translates this blueprint into reality.

The system’s core value lies in formally establishing a dual-track industry development path that combines “strategic purchasing by medical insurance” with “market-based autonomous pricing.” Beyond the track of “basic coverage provided by medical insurance,” the system creates an independent “second track” for innovative drugs to access market-oriented payment channels, such as commercial health insurance. On this track, enterprises can set and register their prices autonomously, following international practices, based on the drug’s level of clinical innovation, R&D costs, and global pricing of comparable products. This “price certificate,” registered on the national platform, effectively demonstrates the product’s differentiated value in the Chinese market to overseas regulators and payers, shielding it from the anchoring effect of domestic inclusive medical insurance prices and thereby securing a more favorable position in overseas negotiations.

This constitutes a concrete implementation of the requirements set forth in the "Several Measures" to “explore more stringent price confidentiality mechanisms” and “support the global expansion of innovative drugs.” It means that an innovative drug can assume “two identities with two pricing structures” in China: one is the “medical insurance identity,” which ensures accessibility for the broadest population; the other is the “market identity,” which caters to diverse needs and reflects the value of innovation. The price associated with the latter will serve as a strong leverage point for competing in the global market, truly enabling high-quality products to command premium prices abroad. The higher returns generated from this approach will, in turn, feed back into sustained R&D and innovation, creating a virtuous cycle.

The establishment of China’s Drug Price Registration System has provided a “Chinese solution” to resolving this contradiction. It sends a clear signal to the world that China not only possesses the world’s largest basic medical insurance network but is also rapidly cultivating a high-value innovative drug market characterized by transparent rules and diversified payment mechanisms.